Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
NCT03083431Phase 2Recruiting
- Sponsor
- University of Zurich
- Start
- Sep 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in retinopathy of prematurity (ROP) comparing Propranolol with Placebo (2 arms). Primary endpoint: Survival without adverse ophthalmological outcome (stage >= 3, AP-ROP, or any ROP treatment). Started Sep 2022; status: recruiting.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT03083431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083431.